Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hirotoshi Watanabe

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Nature Reviews. Cardiology|June 13, 2022
P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventionDavide Capodanno, Usman Baber, Deepak L Bhatt, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 17, 2023
Dual Antiplatelet Therapy Duration After Multivessel Optimal Intravascular Ultrasound-Guided Percutaneous Coronary InterventionKo Yamamoto, Hiroki Shiomi, Takeshi Morimoto, et al.
BMJ (Clinical Research Ed.)|June 17, 2021
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trialsMarco Valgimigli, Felice Gragnano, Mattia Branca, et al.
Journal of the American College of Cardiology|February 8, 2023
P2Y<sub>12</sub> Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary InterventionsFelice Gragnano, Roxana Mehran, Mattia Branca, et al.
JACC. Asia|August 24, 2023
Single-Session Versus Staged Multivessel Optimal IVUS-Guided PCI in Patients With CCS or NSTE-ACSKo Yamamoto, Hiroki Shiomi, Takeshi Morimoto, et al.
JAMA Cardiology|March 2, 2022
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical TrialHirotoshi Watanabe, Takeshi Morimoto, Masahiro Natsuaki, et al.
JAMA|June 26, 2019
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical TrialHirotoshi Watanabe, Takenori Domei, Takeshi Morimoto, et al.
Cardiovascular Intervention and Therapeutics|February 23, 2020
Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trialHirotoshi Watanabe, Takenori Domei, Takeshi Morimoto, et al.
JACC. Asia|March 6, 2023
Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCIKo Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 10, 2020
Application of the Modified High Bleeding Risk Criteria for Japanese Patients in an All-Comers Registry of Percutaneous Coronary Intervention　- From the CREDO-Kyoto Registry Cohort-3Masahiro Natsuaki, Takeshi Morimoto, Hiroki Shiomi, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Nature Reviews. Cardiology|June 13, 2022
P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventionDavide Capodanno, Usman Baber, Deepak L Bhatt, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|May 17, 2023
Dual Antiplatelet Therapy Duration After Multivessel Optimal Intravascular Ultrasound-Guided Percutaneous Coronary InterventionKo Yamamoto, Hiroki Shiomi, Takeshi Morimoto, et al.
BMJ (Clinical Research Ed.)|June 17, 2021
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trialsMarco Valgimigli, Felice Gragnano, Mattia Branca, et al.
Journal of the American College of Cardiology|February 8, 2023
P2Y<sub>12</sub> Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary InterventionsFelice Gragnano, Roxana Mehran, Mattia Branca, et al.
JACC. Asia|August 24, 2023
Single-Session Versus Staged Multivessel Optimal IVUS-Guided PCI in Patients With CCS or NSTE-ACSKo Yamamoto, Hiroki Shiomi, Takeshi Morimoto, et al.
JAMA Cardiology|March 2, 2022
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical TrialHirotoshi Watanabe, Takeshi Morimoto, Masahiro Natsuaki, et al.
JAMA|June 26, 2019
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical TrialHirotoshi Watanabe, Takenori Domei, Takeshi Morimoto, et al.
Cardiovascular Intervention and Therapeutics|February 23, 2020
Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trialHirotoshi Watanabe, Takenori Domei, Takeshi Morimoto, et al.
JACC. Asia|March 6, 2023
Clopidogrel Monotherapy After 1-Month DAPT in Patients With High Bleeding Risk or Complex PCIKo Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|December 10, 2020
Application of the Modified High Bleeding Risk Criteria for Japanese Patients in an All-Comers Registry of Percutaneous Coronary Intervention　- From the CREDO-Kyoto Registry Cohort-3Masahiro Natsuaki, Takeshi Morimoto, Hiroki Shiomi, et al.
Pageof 11